Introduction
Minor histocompatibility (H) antigens represent serious barriers for succesf ul organ and bone marrow transplantation (BMT) between individuals matched for the major histocompatibility complex (MHC) antigens. Minor Η antigens in general fail to induce Β cell responses and are characterized by MHC-restricted Τ cell responses [1, 2] . Due to the lack of available antibodies, thus far little is known concerning the genes encoding human minor Η antigens and their polymorphic gene produets [3] . Recently, it has become evident that, like virus-speeifie cytotoxic Τ lymphocytes (CTL) [4, 5] , MHC class I-restricted CTL speeifie for minor Η antigens recognize short protein Stretches presented by the restricting MHC class I molecule [6-8j . Another line of investigation revealed that MHC class I molecules bind and pfesent an allele-specific set of seif peptides, presumably derived from cellular proteins [9-11]. We set out to isolate CTL-defined human minor Η peptides from the pool of peptides naturally presented by HLA-A2.1. In this report we attempted to characterize two 2 Materials and methods
CTL and Β cell eultures
EBV-transformed Β cell lines (EBV-BLCL) were expanded in RPMI1640 supplemented with 10% FCS and antibiotics in 1 1 roller-bottle flasks. CTL clone 1R35 speeifie for the male minor Η antigen H-Y in the context of HLA-A2.1 was obtained from PBMC of a female immunized against H-Yas a result of multiple transfusions and unsuccesful grafting of HLA-identical male bone marrow [12] . CTL clone 5H17 speeifie for the HLA-A2.1-restricted minor HA-2 was obtained from PBMC of a patient shortly after HLAidentical bone marrow transplantation [2] . Both minor H-specific CTL lines were established by repeated in vitro restimulation with the original stimulator PBMC. After limiting dilution, clones were maintained by weekly Stimulation with allogeneic feeder cells in RPMI 1640 supplemented with 15% pooled human serum and 20 U/ml rIL-2. Immunogenetic data and tissue expression of the HA-2 minor Η antigen were previously described [3, 13] .
Purification of HLA-A2.1 and Isolation of HLA-A2.1 bound peptides
Pellets of 6 x 10 10 EBV-BLCL were ineubated for 45 min at 4 °C at 2 x 10 8 cells/ml in a Iysis buffer containing 50 mM Tris, 150 mM NaCl, 0.5% Nonidet P-40,5 mM EDTA, pH 8 and 0.1 mM PMSF and 1 μg/ml of the protease inhibitors antipain, leupeptin, chymostatin and pepstatin. Centrifugation for 5 min at 500 χ g followed by 60 min at lOOOOxg 0014-2980/93/030V Natur.il minoi Η peptiue yielded a supernatant which was used to punfy HLA-A2 1 by affinity chromatography The antibodies 7 5 10 1 (anti-HLA class II) and BB7 2 (anti-HLA-A2 1. [14] ) were coupled at 5 mg/ml to CNBr-activated Sepharose 4B beads (Pharmacia LKB) The supernatant was sequentially passed, at a flow rate of 8 ml/h, through columns filled with Tns-HCl equihbrated beads (10 ml), anti-HLA class II beads (2 ml) and two columns with anti-HLA-A2 1 beads (7 and 4 ml) Beads were removed from anti-HLA-A2 1 columns and mcubated for 15 min at 4 °C in 15 ml 0 1% tnfluoroacetic acid (TFA) Supernatants were separated by centnfugation over Centncon 10 (Amicon) filters into a > 10 kDa and a < 10 kDa fraction.The amount ot puntied HLA-A2 was determined with the BCA protein assay (Pierce) in the > 10 kDa fraction Punfication grade was monitored b\ siKer-stamed SDS-PAGE The IO\A and high molecular weight tractions ot HLA-A2 1 were dned b\ saeuum centntugation and separated b\ rc\crsc-phasc HPLC using a^LiChrospher 60 RP-Select B. 5 um. 250 χ 4 mm column (E Merck. Darmstadt. FRG) Elution butters were A. H : O, B. ucetonitnle: and C. 2% TFA in HiO Gradients routinclv used for separations 0-30 mm linear increase trom 5% to 75% Β or 0-45 min linear increase trom 20% to 50% B. with 5% butter C being used throughout all gradients. flow rate 1 0 ml/mm Elution was monitored b\ a continuous flow spectrophotometer at 214 nm Fractions ot 1 or 0 5 ml were collected and dned b\ \acuum centntugation
Pepiide sequencing and synthesis
Low molecular weight matenal eluted trom HL A-A2 1 and separated by HPLC was sequenced by automated Edman degradation using a pulsed-hquid protein sequencer 477A equipped with an on-line PTH-amino acid analyzer 120A (Applied Biosystems) Mixturesot synthetic peptides were generated dunng mixed syntheses using an AMS 
Results
HLA-A2.1 was punfied by affinity chromatography [9] from an HLA-A2.1 + EBV-BLCL expressing both H-Yand HA-2 minor Η antigens. In total 3.3 mg protein was eluted from the anti-HLA-A2.1 mAb-coated columns. SDS-PAGE and reverse-ohase HPLC revealed that this matenal mainly represented ß2-microglobulin (ß2m) and Η chain (Fig la, b) . Quantification of the HPLC ß2m peak, by companson with peak sizes of known amounts punfied ß2m, indicated that 127 μg or 2.35 nmol HLA-A2.1 was recovered alter HPLC. Naturally bound peptides copunfied with HLA-A2.1 were separated from ß2m and Η chain by acid treatment followed by ultrafiltration (cutoff 616 10 kDa). Low molecular mass molecules (< 10 kDa) were fractionated by reverse-phase HPLC (Fig. 2A) . Individual fractions were then tested for recognition by HLA-A2.1-restricted CTL specific for H-Y (Fig. 2B ) and for HA-2 (Fig. 2C) . None of the fractions rendered HLA-A2.1 + female EBV-BLCL susceptible to lysis by anti-H-Y CTL (Fig. 2B) . In contrast. HLA-A2.1\ HA-2~ BLCL incubated with fraction 18 were effectively lysed by anti-HA-2 CTL (Fig. 2C) . whereas none of the other fractions could sensitize the target cells for HA-2. Fraction 18 could be diluted more than 2000-fold and still sensitize target cells for HA-2 recognition (Fig. 2D) . Comparable HA-2-sensitizing activity was found in HPLC fraction 18 of unseparated HLA-A2.1. but not in the high molecular mass (> 10 kDA) material of filtered HLA-A2.1 (not shown). HA-2 reproducibly eluted in one fraction at a constant position in the HPLC spectrum. Repeated Isolation of the peptide content of HLA-A2.1 molecules derived from 4 x 10 10 EBV-BLCL yielded identical results (data not shown).
The HA-2-containing fraction 18 was sequenced by Edman degradation and found to contain more than one peptide ( Table 1) . None of the peptides was more than nine amino acids in length. Α dominant Leu was found at positions 2 and 9. Tb obtain a purer fraction. containing only the HA-2 peptide, a second HLA-A2.1 peptide pool was separated by HPLC using a shallower gradient (20-50% in 45 min with 0.5 ml fractions instead of 5-75% in 30 min with 1 ml fractions). Subsequent cell-mediated lysis analysis indicated two fractions with HA-2 activity. However, sequenee analysis of the pooled fractions revealed again a nonapeptide mixture with virtually identical amino acids as found in fraction 18 (see Table 1 ).
To identify which of the eluted nonapeptides represented the naturally processed HA-2 minor peptide, eight mixtures of nonapeptides covering all peptides possibly present in fraction 18 (see Sect. 2.3) were synthesized, fractionated by HPLC and tested for their ability to induce lysis by anti-HA-2 CTL. However, none of the peptide mixtures could sensitize HA-2" BLCL for recognition by anti-HA-2 CTL at concentrations as high as 500 pM (data not shown).
Discussion
Minor Η antigen HA-2 was initially defined by HLA-A2.1-restricted CTL isolated from PBL after MHC-identical, HA-2-mismatched BMT [2] . The HA-2+ phenotype has a frequency of 95% in the HLA-A2.1+ population [3] . In contrast to the previously isolated murine minor Η peptides H-Y and H-4 b which are ubiquitously expressed, HA-2 is expressed only by cells of hematopoietic origin [13] . In the Situation of MHC-matched, HA-2-mismatched BMT, therefore, these anti HA-2 CTL are not likely to inflict graft-versus-host (GVH) reactions (GVH-target tissues, e.g. the skin, does not express HA-2), but might be involved in the so-called graft-versus-leukemia effect [15] . Here, the natural HA-2 peptide presented by HLA-A2.1 to CTL is shown to be present within an HLA-A2.1 peptide fraction containing predominantly nonapeptides with Leu as dominant amino acid at positions 2 and 9. Thus, this finding is compatible with two previous reports indicating that naturally processed HLA-A2.1-bound seif peptides are mainly nonapeptides and carry Leu at position 2 and either Leu or Val at the carboxy-terminal position 9 [9, 10] .
Unexpectedly, however, none of the synthetic peptide mixtures, covenng all nonamenc sequences indicated by the observed HLA-A2 1 binding motif (Table 1) , cou!d sensitize HA-2~ BLCL for recognition by anti-HA-2 CTL The failure to detect the HA-2 peptide in the peptide mixtures based on the observed A2 1 motif might be due to (1) competition for binding to HLA-A2 1 between the peptides present in each tested mixture, or (2) absence of the HA-2 amino acid sequence among the senes of synthetic peptides tested At this stage we cannot rule out the first possibihty Additional separate testing will be required to exclude the possibihty of competition The second explanation would indicate that the amount of HA-2 peptide present in fraction 18 was insufficient to be detected Should fraction 18 (100 pmol total peptide content based on Edman degradation) contain 20 or more different peptides in equimolar amounts, 1 of which being HA-2, then HA-2 would already be below the detection hmit of the PTH amino acid analyzer used (5 pmol) Given the recent estimate that the HLA-A2 1 molecules of a given cell might contain 200 to 1000 distinct nonapeptides [10] , this explanation IS not unhkely These results stress the enormous sensitivity of a CTL in detecting peptide in the context of an MHC class I molecule Anti-HA-2 CTL could detect as little as 1 in 1920 of the matenal of fraction 18 which apparently contamed insufficient of the HA-2 peptide to be measured by Edman degradation Our observations are in hne with previous reports on the Isolation of minor Η peptides from lysates of whole cells The munne H-2 b -restncted minor Η antigens H-Y, H-4 b and Mapki and an HLA-B35-restncted antigen were detectable by the appropnate CTL, but could not be identified as Single peptides [5] [6] [7] Recent sequence analysis of the self-peptide pool present in HLA-A2 1 and HLA-B27 revealed the presence of a hmited number of "dominant" peptides which were present in sufficient amounts to allow sequence analysis [10, 11] Our mabihty to elucidate the amino acid sequence within the peptide pool denved from 2 35 nmol HLA-A2 1 may indicate that this minor Η peptide is not present in comparable amounts to those "dominant" seif peptides of which sufficient copies are available to allow Identification as Single peptides and which determine the peptide-binding profile In fact, lt can not be excluded at this point that seif peptides, present in quantities undetectable with the current biochemical methods, may not follow the MHC class I allele-specific binding rules based on the composition of the abundant peptides The fact that HLA-A2 1-restncted CTL epitopes exist, defined by synthetic peptides which do not fit the HLA-A2 1 binding protile determined thus far, would be compatible with this hypothesis [16, 17] Starting with larger amounts of punfied MHC class I (here 6 x 10 10 cells were used, yielding 2 35 nmol pure HLA-A2 1 after HPLC) may allow detection of these minor peptides and determination of MHC class I binding profiles in more detail Our inabihty to detect the H-Y, in contrast to the HA-2, peptide thus tar could be due to (a) a lower number of ΗΎ peptides per HLA-A2 1 molecule. (b) mabihty of H-Y to rcplace endogenously bound seif peptides in vitro due to a lower aitinit> or (c) selective loss of H-Ydunng punfication At this point we cannot exclude any of these possihilmes Future punfication ot H-Y peptides from icii^er amounts of HLA-A2 1 as suggested earher may lead to its detection Although the first human minor Η protein still awaits Identification, in the mouse polymorphic seif proteins located in the cytosol [18] and in mitochondria [19] , as well as proteins encoded by retroviral genes [20] , can represent minor Η proteins. ι e induce MHC class I-restncted CTL and skin-graft rejection From this, it may be concluded that within any given cell a large source of potential minor Η proteins might be present Fortunately, based on the recent understanding of the MHC class I-processing pathway, it may be expected that only a small and selected fraction of the total pool of peptides denved from these proteins will make it to the cell surface, and that again onl> a selected fraction of these cell surface peptides will manifest itself as minor Η peptide Cntena resulting in this peptide selection will include (1) a sufficiently high affinity for binding to one of the available MHC class I molecules, (2) presence ofa sufficient number of copies resulting in the minimal number of MHC-peptide complexes at the cell surface required forTcell activation [21] , and (3) polymorphism of the peptide and immunogenicity of the MHCpeptide complex formed Should, in contrast to the total number of distinct class I-bound cell surface peptides (estimated 200-1000 for HLA-A2 1), the number of Τ cellactivating minor Η peptides per MHC class I allele be hmited to a few or even one, then clmical apphcations in minor H-mismatched BMT would beiong to the future possibihties
